Company news
Initiator Pharma A/S news in 2025
Initiator Pharma A/S's news releases, calls and decks from 2025, newest first.
Initiator Pharma to attend J.P. Morgan Healthcare Conference in San Francisco
December 23, 2025
INIT: Advanced clinical pipeline and secured major financing, with focus on vulvodynia and ED markets
November 21, 2025
INIT: First-in-class therapy for vulvodynia enters pivotal trial, targeting a multibillion-euro market
November 17, 2025
Initiator Pharma Gets UK CTA Approval For Phase 2a Study
November 3, 2025
Initiator Pharma A/S: Quarterly Trading Report 2025 Q3
October 3, 2025
INIT: Pudafensine advances to Phase II for vulvodynia, targeting major unmet needs in women's health
September 25, 2025
INIT: Pudafensine advanced to Phase IIa for vulvodynia, with strong funding and reduced Q2 losses
August 22, 2025
INIT: Q1 2025 saw reduced losses and clinical progress in ED, FSD, and pain programs
May 9, 2025
INIT: Reduced losses and clinical progress in ED and FSD position Initiator Pharma for future growth
February 28, 2025